FindTrial
Sign In

Effects of Aerobidol® Inhaler on pulmonary function in COPD patients

Effects of Aerobidol® Inhaler on pulmonary function test parameters compared with Berodual® in COPD patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20150210001
Enrollment
Unknown
Registered
2015-02-10
Start date
2015-02-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease Aerobidol COPD pulmonary function FEV1 RV

Interventions

Aerobidol Inhaler is a trade name of locally made product which have dose and components similar to Berodual.,Berodual is a trade name of original product bronchodilator
in one puff of metered dose inhaler composed of ipratropium bromide 20 micrograms and fenoterol hydrobromide 50 micrograms.
Experimental Drug,Active Comparator Drug
Aerobidol Inhaler,Berodual

Sponsors

AeroCare Co.,Ltd
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients aged more than 40 years, smoking more than 10 packyears who diagnosed with COPD by spirometry (post bronchodilator FEV1/FVC less than 70%)

Exclusion criteria

Exclusion criteria: Patients who cannot perform body plethysmography COPD patients who have medical disease such as lung cancer, bronchiectasis, severe tracheobronchomalacia Patients who refuse to join the study

Design outcomes

Primary

MeasureTime frame
FEV1, FVC, IC, RV, TLC 2 (pre-,post-) body plethysmography—

Secondary

MeasureTime frame
satisfaction score, side effects 1 questionnaire—

Countries

Thailand

Contacts

Public ContactKamon Kawkitinarong
kamonkaw@hotmail.com0813111501

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026